1. 514 Results of Phase 1b trial of the Indoleamine 2, 3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma. (September 2015) Authors: Zakharia, Y.; Drabick, J.; Khleif, S.; Munn, D.; Link, C.; Vahanian, N.; Kennedy, E.; Rixe, O.; Milhem, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors. (September 2015) Authors: Nayak, A.; Hao, Z.; Sadek, R.; Dobbins, R.; Marshall, L.; Vahanian, N.; Ramsey, J.; Kennedy, E.; Mautino, M.; Link, C.; Lin, R.; Royer-Joo, S.; Morrissey, K.; Mahrus, S.; McCall, B.; Pirzkall, A.; Munn, D.; Janik, J.; Khleif, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Using real-world evidence to understand the symptom experience and concerns of older adults with cancer: Age-analysis of patient-reported outcome measures routinely collected in Alberta, Canada. (October 2022) Authors: Strohschein, F.; Qi, S.; Link, C.; Davidson, S.; Watson, L. Journal: Journal of geriatric oncology Issue: Volume 13(2022)Supplement 1 Page Start: S34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗